All In MedTech

FDA Clearance Tracker · P150013-S016

PD-L1 IHC 22C3 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 30, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 30, 2019

Approved

Time to decision

155 days

Received Feb 25, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150013-S016
Device name
PD-L1 IHC 22C3 pharmDx
Applicant location
Santa Clara, CA
Received
Feb 25, 2019
Decided
Jul 30, 2019
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150013

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the PD-L1 IHC 22C3 pharmDx. PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using monoclonal mouse anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC), cervical cancer, urothelial carcinoma and head and neck squamous cell carcinoma (HNSCC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. PD-L1 protein expression in gastric or GEJ adenocarcinoma, ESCC, cervical cancer, urothelial carcinoma and HNSCC is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.Companion Diagnostic IndicationsTumor Indication PD-L1 Expression Level Intended UseNSCLC TPS greater than or equal to 1% PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). **Gastric or GEJ Adenocarcinoma CPS greater than or equal to 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA® (pembrolizumab).ESCC CPS greater than or equal to 10 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying esophageal squamous cell cancer patients for treatment with KEYTRUDA® (pembrolizumab). Cervical Cancer CPS greater than or equal to 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab).Urothelial Carcinoma CPS greater than or equal to 10 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying urothelial carcinoma patients for treatment with KEYTRUDA® (pembrolizumab). **HNSCC CPS 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying HNSCC patients for treatment with KEYTRUDA® (pembrolizumab). ****See the KEYTRUDA® product label for specific clinical circumstances guiding PD-L1 testing.For in vitro diagnostic use.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.